RSA Places CEO at Actinium Pharmaceuticals

September 24, 2012 – RSA, a global life sciences executive search and interim management specialist, has placed Jack Talley as president and chief executive officer of Actinium Pharmaceuticals, Inc. Shawn O’Connor, president of RSA Americas, stated: “We are delighted to conclude our search with the placement of such an exceptional candidate. Previously the CEO of EpiCept Corporation, Jack has immense experience in the industry and we believe he is well positioned to succeed in his new role.” A private biopharmaceutical company, Actinium develops innovative targeted radio-immunotherapeutics to treat various cancers.